Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that

The unquenchable demand for weight reduction medications is causing a shortage, leaving many patients unable to obtain injectable treatments. 

Novo Nordisk and Eli Lilly are the top weight loss drugmakers.

have stated that supply issues would most certainly persist as the popularity of those medications grows. However, both corporations are making positive headway in their attempts to boost supply. 

"I think it's going to take a few years for it to resolve itself," Cantor Fitzgerald analyst Louise Chen told CNBC. "But I think both companies will slowly start to meet the demand in the market." 

Patients have gravitated to weight loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound because they help them lose large pounds over time, despite the pills' high prices, mixed insurance coverage, and a handful of nasty side effects.

Goldman Sachs analysts predict that 15 million persons in the United States will be taking obesity drugs by 2030. 

Some Wall Street analysts predict that the weight-loss medicine market will be worth $100 billion by the end of the decade.

As demand rises, most medications are experiencing sporadic shortages. However, there is limited data on how severe the shortages are or how much supplies companies have.

Love Horoscope For February 1, 2024 Brings Change

For More WebStories